Healthcare Triangle is trading 18.83% lower at $3.75 as investors focus on its November 5 Nasdaq appeal hearing over a minimum-bid-price delisting determination. - The company completed a 1-for-20 reverse split as part of its plan to regain compliance. - The hearing’s outcome will determine whether Healthcare Triangle can maintain its listing. - A sharp technology selloff, fueled by concerns about AI regulation and investment, is adding broader sector pressure.